Lymphocyte-Directed Immunomodulation Remits Thymoma-Associated Autoimmune Pneumonitis

Area of Science:

• Immunology
• Pulmonology
• Oncology

Background:

• Thymoma is linked to autoimmune disorders and autoimmune regulator (AIRE) deficiency.
• Autoimmune pneumonitis associated with thymoma shares features with inherited AIRE deficiency syndromes like APECED.
• This highlights a potential autoimmune component in thymoma-related lung disease.

Purpose of the Study:

• To investigate the efficacy of lymphocyte-directed immunomodulation for thymoma-associated pneumonitis.
• To evaluate treatment outcomes in patients with biopsy-proven thymoma and pneumonitis.

Main Methods:

• Two thymoma patients with pneumonitis underwent lymphocyte-directed immunomodulation (azathioprine +/- rituximab).
• Comprehensive evaluations included clinical, laboratory, radiographic, and pulmonary function tests.
• Lung-specific autoantibodies (KCNRG, BPIFB1) were measured pre- and post-treatment.

Main Results:

• Combination T- and B-lymphocyte immunomodulation improved clinical, functional, and radiographic parameters.
• Both patients achieved sustained remission for 12-36 months post-treatment.
• Significant improvements were observed at 6-month follow-up.

Conclusions:

• Lymphocyte-directed immunomodulation successfully remitted autoimmune pneumonitis in thymoma patients.
• This therapeutic strategy shows promise for managing thymoma-associated autoimmune lung disease.